---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-041298"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2026-06-05T20:38:13+00:00"
generated_at: "2026-06-05T20:41:39.346541+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Vanda shareholders re-elect three Class II directors and approve equity plan amendment

## Summary
- Directors Dugan, Duncan, and Ward re-elected with majority support; broker non-votes of ~10M shares.
- Shareholders ratified PwC as auditor for FY 2026 with 48.1M votes for.
- Advisory say-on-pay passed; ~35.2M for, ~3.2M against.
- Amendment to 2016 Equity Plan to increase authorized shares approved with 31.7M for, 6.7M against.

## SEC filing metadata
- accession: 0001628280-26-041298
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2026-06-05T20:38:13+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/0001628280-26-041298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/vnda-20260604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-041298
- JSON: https://secwatch.observer/filing/0001628280-26-041298.json
- Plain text: https://secwatch.observer/filing/0001628280-26-041298.txt

## Key facts
- Shareholder Votes
  Vanda Pharmaceuticals Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders ratified the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/0001628280-26-041298-index.htm
- Shareholder Votes
  Vanda Pharmaceuticals Inc. shareholders approved Advisory vote on named executive officer compensation at the 2026-06-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders approved on an advisory, non-binding basis the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/0001628280-26-041298-index.htm
- Shareholder Votes
  Vanda Pharmaceuticals Inc. shareholders approved Election of three directors to serve as Class II directors for a term of three years until the Company's 2029 annual meeting of stockholders at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders elected the following directors to serve as Class II directors until the Company’s 2029 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/0001628280-26-041298-index.htm
- Shareholder Votes
  Vanda Pharmaceuticals Inc. shareholders approved Amendment to Company's Amended and Restated 2016 Equity Incentive Plan to increase aggregate number of shares authorized for issuance at the 2026-06-04 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders approved an amendment to the 2016 Plan to increase the aggregate number of shares authorized for issuance under the 2016 Plan.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/0001628280-26-041298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.